Crystals of prasugrel hydrobromate
The present application discloses crystals of 2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrobromate, crystal compositions and pharmaceutical compositions comprising them and their use. The crystals of prasugrel hydrobromate of the present application possess excellent stability and solubility.
1. A crystal of a compound having formula II:
wherein:
Sol is acetic acid; and
m is 1.
2. The crystal of claim 1 , wherein in an X-ray powder diffraction pattern of the crystal measured with Cu-Kα radiation, diffraction peaks expressed as interplanar spacing d are found at about 10.43 Å, 8.63 Å, 7.20 Å, 6.33 Å, 5.15 Å, and 3.47 Å.
3. The crystal of claim 2 , wherein in the X-ray powder diffraction pattern of the crystal measured with Cu-Kα radiation, diffraction peaks expressed as interplanar spacing d are found at about 10.43 Å, 8.63 Å, 7.20 Å, 6.33 Å, 5.15 Å, 4.80 Å, 4.73 Å, 3.77 Å, 3.68 Å, and 3.47 Å.
4. The crystal of claim 3 , wherein in the X-ray powder diffraction pattern of the crystal measured with Cu-Kα radiation, diffraction peaks expressed as interplanar spacing d are found at about 12.38 Å, 10.43 Å, 8.63 Å, 7.20 Å, 6.33 Å, 5.15 Å, 4.96 Å, 4.80 Å, 4.73 Å, 4.02 Å, 3.77 Å, 3.68 Å, 3.47 Å, 3.36 Å, 2.99 Å, and 2.95 Å.
5. The crystal of claim 1 , wherein the crystal is of orthorhombic structure, and the space group thereof is Pnma; the lattice parameters thereof approximately are: a=15.33 Å; b=7.39 Å; c=20.82 Å; α=β=γ=90′; and the lattice volume thereof is 2356.89 Å 3 .
6. A pharmaceutical composition comprising a therapeutically effect amount of a crystal of a compound having formula II:
wherein:
Sol is acetic acid; and
m is 1.
7. A method for preventing diseases associated with thrombus in an animal, comprising administering to the animal in need thereof a therapeutically effective amount of a crystal of a compound having formula II:
wherein:
Sol is acetic acid, and
m is 1.
8. A crystal composition comprising the crystal of claim 1 in an amount of 60% or more by weight.
9. The crystal composition of claim 8 , comprising the crystal of claim 1 in an amount of 90% or more by weight.
10. The crystal composition of claim 8 , comprising the crystal of claim 1 in an amount of 95% or more by weight.
11. The crystal composition of claim 8 , comprising the crystal of claim 1 in an amount of 99% or more by weight.